Phaseline

Companies › Huons

Huons: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HUC3-637-R–Phase 3Primary Open Angle Glaucoma (POAG)Nov 2027
HUC1-394–Phase 2Dry Eye Disease (DED)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07656688HUC1-394Phase 2Dry Eye Disease (DED)OphthalmologyJun 2027
NCT07335211HUC3-637-RPhase 3Primary Open Angle Glaucoma (POAG)OphthalmologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Taejoon Pharmaceutical SANGMYUNG innovation Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.